Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03194347 | Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas(MAGynMA) | completed | — | 300 | University Hospital TuebingenOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04587050 | Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV(SHiP) | completed | — | 57 | Imperial College LondonOTHER | 1 |
| Dec 10, 2024 |
| clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03745950 | UTOLA: UTerin OLAparib(UTOLA) | completed | Phase 2 | 147 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT06705309 | Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer | completed | N/A | 128 | Istanbul University - CerrahpasaOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03207126 | Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? | completed | N/A | 10 | Imperial College LondonOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700941 | Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment | completed | — | 8,000,000 | Universidad Nacional de ColombiaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02054351 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)(OVAR) | completed | Phase 1 | 42 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03159572 | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations(HITOMI) | completed | — | 996 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT06697613 | Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer | completed | — | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04525183 | REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | completed | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04274465 | Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia | completed | — | 145 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT00170625 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT04434066 | Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy | completed | N/A | 46 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681831 | Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer | completed | N/A | 15 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05862844 | Promise Women Project | completed | N/A | 20 | Mark Dignan, PhDOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04458168 | Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living | completed | N/A | 120 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT03551028 | HPV DNA Testing Through Mobile Mammography Unit | completed | N/A | 33 | University of VirginiaOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05227651 | AK104 in Neoadjuvant Treatment of Cervical Cancer | completed | Phase 2 | 14 | AkesoINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03308591 | Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients | completed | Phase 3 | 774 | Huazhong University of Science and TechnologyOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03378297 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC(IMPACT) | completed | Early Phase 1 | 26 | Haukeland University HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT01600040 | Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix | completed | N/A | 22 | Massachusetts General HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | completed | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT05427214 | Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy(Dragon) | completed | N/A | 52 | Washington University School of MedicineOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05959564 | A Chatbot Intervention for Reducing HPV Vaccine Hesitancy | completed | N/A | 456 | University of Maryland, College ParkOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03596281 | Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer(PEMBOV) | completed | Phase 1 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04258631 | Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies | completed | Phase 4 | 105 | Mayo ClinicOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644677 | Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06313268 | Safety of Effivia®, a Bevacizumab Biosimilar | completed | — | 83 | Laboratorios LiomontINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06629831 | Systemic Inflammatory Biomarkers in Ovarian Cancer | completed | — | 90 | Bakirkoy Dr. Sadi Konuk Research and Training HospitalOTHER_GOV | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04927013 | Connecting Families to Overcome Ovarian Cancer | completed | N/A | 2,331 | Emory UniversityOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06623916 | Strain-elastography in Endometrial Cancer | completed | — | 63 | Alper seyhanOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05359952 | Women's Health Communication Study | completed | N/A | 32 | Fox Chase Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT05775549 | A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer(FLAME) | completed | — | 24 | AstraZenecaINDUSTRY | 1 | Sep 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2024source: clinicaltrials